Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials

American Journal of Emergency Medicine

Volumn 27, Issue 6, 2009, Pages 683-690

  De Luca, Giuseppe ^a   Marino, Paolo ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; DUTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; RETEPLASE; TENECTEPLASE; TIROFIBAN;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HEART REINFARCTION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 67649947214     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2008.05.021     Document Type: Article

References (36)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 61 (2003) 13-20
2. Shavelle D.M., Rasouli M.L., Frederick P., et al. National Registry of Myocardial Infarction Investigators. Outcome in patients transferred for percutaneous coronary intervention (a National Registry of Myocardial Infarction 2/3/4 analysis). Am J Cardiol 96 (2005) 1227-1232
3. De Luca G., Suryapranata H., Ottervanger J.P., et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004) 1223-1225
4. Brodie B.R., Stuckey T.D., Muncy D.B., et al. Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J 145 (2003) 708-715
5. ASSENT-4 PCI investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
6. Ellis S. The FINESSE Trial (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events). http://www.escardio.org/congresses/esc_congress/esc2007/news/HLIIFinesseEllisVDWerf.htm.
7. Peters S., Truemmel M., and Koehler B. Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial. Int J Cardiol (2007) [Electronic publication ahead of print]
8. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367 (2006) 579-588
9. Sinno M.C., Khanal S., Al-Mallah M.H., et al. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Am Heart J 153 (2007) 579-586
10. Egger M., and Smith G.D. Bias in location and selection of studies. BMJ 31 (1998) 61-66
11. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
12. ADVANCE AMI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 150 (2005) 116-122
13. The SPEED Study Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 101 (2000) 2788-2794
14. Wong A., Mak K.H., Chan C., et al. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. Catheter Cardiovasc Interv 62 (2004) 445-452
15. Kastrati A., Mehilli J., Schlotterbeck K., et al. Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 291 (2004) 947-954
16. Coleman C.I., McKay R.G., Boden W.E., et al. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals. Clin Ther 28 (2006) 1054-1062
17. Tarantini G., Razzolini R., Ramondo A., et al. Explanation for the survival benefit of primary angioplasty over thrombolytic therapy in patients with ST-elevation acute myocardial infarction. Am J Cardiol 96 11 (2005) 1503-1505 [Electronic publication 2005 Oct 11]
18. Nallamothu B.K., Antman E.M., and Bates E.R. Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment?. Am J Cardiol 94 (2004) 772-774
19. Betriu A., and Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 95 (2005) 100-101
20. Montalescot G., Barragan P., Wittenberg O., et al. ADMIRAL Investigators. Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
21. van 't Hof A.W., Ernst N., de Boer M.J., et al., On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25 (2004) 837-846
22. Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26 (2005) 1971-1977
23. Cutlip D.E., Ricciardi M.J., Ling F.S., et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92 (2003) 977-980
24. Zorman S., Zorman D., and Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 90 (2002) 533-536
25. Lee D.P., Herity N.A., Hiatt B.L., et al. TIrofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 107 (2003) 1497-1501
26. Maioli M., Bellandi F., Leoncini M., et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 10 49 (2007) 1517-1524
27. Rakowski T., Zalewski J., Legutko J., et al. Impact of early abciximab administration before primary percutaneous coronary intervention in Anterior Myocardial infarction on reperfusion and left ventricular function. Am J Cardiol 96 Suppl 7A (2005) 27H
28. Arntz H.R., Schroder J., and Schwimmbeck P. Is early prehospital administration of abciximab superior to periprocedural therapy in patients with STEMI and planned PCI? Early and late results from the randomized REOMOBILE Pilot study. J Am Coll Cardiol 43 Suppl A (2004)
29. Gabriel M.H., Oliveira J., and Canas da Silva P. Early administration of abciximab bolus in the emergency room improves microperfusion after primary coronary intervention, as assessed by TIMI frame count; results of the ERAMI trial. Eur Heart J 24 Abstract Supplement (2003) 543
30. Gyöngyösi M., Domanovits H., Benzer W., et al., ReoPro-BRIDGING Study Group. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 25 (2004) 2125-2133
31. Emre A., Ucer E., Yesilcimen K., et al. Impact of early tirofiban on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 106 (2006) 264-269
32. Gibson C.M., Kirtane A.J., Murphy S.A., et al., TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 152 (2006) 668-675
33. Montalescot G., Borentain M., Payot L., et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 292 (2004) 362-366
34. Dudek D., Siudak Z., Janzon M., et al. Patients transferred for primary PCI display reduced mortality when treatment with abciximab was started early compared with abciximab given in the cathlab. Results from the EUROTRANSFER Registry. Eur Heart J 28 Abstract Supplement (2007) 384
35. Huber K., Aylward P.E., van't Hof A.W.J., et al. Glycoprotein IIb-IIIa inhibitors before primary percutaneous coronary intervention of ST-elevation myocardial infarction improve perfusion and outcomes: insights from APEX-AMI. Circulation 116 (2007) II-673 [Abstract]
36. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 28 (2007) 443-449